← Volver a todas las respuestas
What Are the Day-to-Day Differences Between Penicillamine and Trientine?
Penicillamine and trientine both remove copper effectively, but their side-effect profiles, dosing schedules, food interactions, and long-term tolerability differ enough to matter for daily life.
Both penicillamine and trientine are copper chelators — they work by binding copper in your body and carrying it out through urine. On paper, they accomplish the same goal. In daily life, the differences can be significant enough to affect which one your specialist recommends for you, and what you can expect from living with each.
How they work and how they compare on effectiveness
Penicillamine has been in use for Wilson disease since the 1950s and has the largest long-term evidence base. It is highly effective at copper removal and, for patients who tolerate it, has a long track record.1 Trientine (triethylenetetramine) was introduced in the 1960s specifically for patients who could not tolerate penicillamine. It is also an effective chelator, though some studies suggest it may mobilize copper somewhat less aggressively in the early phases of treatment.2
Both drugs are endorsed as first-line options by major guidelines.34 The choice between them is now less often about effectiveness and more about individual tolerability, your symptom profile, and in some parts of the world, availability and cost.
Side effects: the biggest practical difference
This is where the two drugs diverge most meaningfully.
Penicillamine carries a broader and more serious side-effect profile. The early sensitivity reactions — fever, rash, worsening of neurological symptoms in the first weeks of treatment — affect a meaningful minority of patients.3 More concerning for long-term use are the autoimmune side effects that can develop over time: drug-induced lupus, kidney problems (including nephrotic syndrome from membranous nephropathy), myasthenia gravis-like syndrome, and skin changes that make the skin fragile and prone to bruising.1 These are not universal, and many patients take penicillamine for decades without serious problems — but they are real enough that your doctor will want regular blood tests and urine tests to watch for them.
The early neurological worsening that can occur when starting penicillamine deserves special mention. For patients who present with neurological Wilson disease, starting penicillamine can paradoxically make symptoms worse in the first weeks, likely because it mobilizes copper rapidly and transiently increases the amount circulating in the brain before it is excreted.5 This does not mean the drug is failing — but it is frightening when it happens, and it is one reason trientine or zinc may be preferred as the first agent in neurological presentations.
Trientine generally has a milder side-effect profile. Serious autoimmune reactions are less common. The main caution with trientine is that it can over-chelate — removing too much copper over time — leading to copper deficiency if doses are not monitored and adjusted as your copper stores normalize.4 Iron deficiency has also been reported. Patients on trientine still need regular monitoring, but the list of feared complications is shorter than with penicillamine.
Dosing and the food interaction problem
Both drugs need to be taken on an empty stomach — away from food — because food, especially food containing minerals, competes with the drugs for absorption and dramatically reduces their effectiveness.3 In practice, this means:
- Take your dose at least one hour before or two hours after eating.
- Avoid mineral supplements (calcium, magnesium, iron, zinc) close to your chelator dose — they interact.
- Dairy products are particularly problematic close to a penicillamine dose because of the calcium content.
This timing constraint is one of the more disruptive aspects of daily life on a chelator, especially if you have a variable schedule, work shifts, or have a young child whose mealtimes are unpredictable. Neither drug offers a simple “with food” option.
Penicillamine is typically dosed multiple times per day. Trientine is also dosed multiple times daily, though some newer extended-release formulations (where available) have changed this for some patients. Ask your specialist what formulation you have access to.
Vitamin B6 and penicillamine
Penicillamine interferes with the activity of vitamin B6 (pyridoxine) in the body. This can cause a peripheral neuropathy if supplementation is not provided. It is standard practice to take a modest B6 supplement alongside penicillamine.1 Trientine does not have this interaction, so patients on trientine do not routinely need vitamin B6 supplementation unless there is another reason for it.
This is a small but concrete daily difference: one more tablet if you are on penicillamine.
Switching between drugs
Patients who develop intolerable side effects on penicillamine are frequently switched to trientine. The evidence for this transition is well-established — a prospective study of patients switched from penicillamine to trientine showed that copper control was maintained in most patients, and that trientine was well tolerated after the switch.2
Switching in the other direction — from trientine to penicillamine — is less common but happens. The point is that your initial choice is not permanent. If one drug is not working for you, or is causing problems, there is an alternative.
You can read more about what happens when you move from initial treatment to maintenance at /post/after-initial-chelation-can-i-switch-to-zinc-monotherapy-for, and for an overview of all treatment options see /post/medications-overview.
Quick comparison table
| Feature | Penicillamine | Trientine |
|---|---|---|
| Years in use | Since 1950s | Since 1960s |
| Copper removal | Highly effective | Effective (slightly less aggressive initially) |
| Early neurological worsening risk | Higher | Lower |
| Autoimmune side effects | More common | Less common |
| Kidney monitoring needed | Yes (nephrotic syndrome risk) | Less acute concern |
| Food timing constraint | Yes (1h before / 2h after) | Yes (1h before / 2h after) |
| Vitamin B6 supplement needed | Yes | No |
| Copper deficiency risk | Present | Present (monitor closely) |
| Cost / availability | More widely available, lower cost in many markets | More expensive; newer generics emerging |
What matters for your daily routine
Whichever drug you take, the practical discipline is the same: consistent timing, consistent monitoring, and honest communication with your specialist about any new symptoms. Neurological symptoms that worsen after starting or changing a chelator — even slightly — should be reported promptly.56
The side-effect differences between penicillamine and trientine are real, but they play out over months and years, not days. The most important factor for most patients is taking their chosen drug reliably and showing up for the regular blood and urine checks. Gaps in treatment are more dangerous than any minor practical inconvenience of either drug. See /post/missed-doses if missed doses are a concern.
This article is patient education, not medical advice. The choice between penicillamine and trientine is individual — it depends on your presentation, your tolerance, your access, and your specialist’s judgment. Please discuss any concerns about your current medication with your Wilson disease team before making changes.
References
-
Czlonkowska, Anna, et al. “Wilson disease.” Nature Reviews Disease Primers 4, no. 1 (2018): article 22. https://doi.org/10.1038/s41572-018-0024-5. ↩↩↩
-
Weiss, Karl Heinz, Jan Pfeiffenberger, Wolfgang Stremmel, Jodie Estall, and Daniel N. Gotthardt. “Prospective Study to Assess Long-Term Outcomes of Treatment with Trientine in Wilson Disease Patients Withdrawn from Therapy with D-Penicillamine.” Journal of Hepatology 64, no. 2 (2016): S293. https://doi.org/10.1016/s0168-8278(16)00368-8. ↩↩
-
Schilsky, Michael L., Eve A. Roberts, Jeffrey M. Bronstein, Anil Dhawan, Diane W. Hamilton, Annette Rivard, Marjorie Washington, Karl Heinz Weiss, and Paula Zimbrean. “A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver Diseases.” Hepatology 82, no. 3 (2025): E41–E90. https://doi.org/10.1002/hep.32801. ↩↩↩
-
European Association for the Study of the Liver. “EASL Clinical Practice Guidelines: Wilson’s disease.” Journal of Hepatology 56, no. 3 (2012): 671–685. https://doi.org/10.1016/j.jhep.2011.11.007. ↩↩
-
Mohr, Ilka, Jan Pfeiffenberger, Banu Eker, Uta Merle, Aurelia Poujois, Alistair Ala, and Karl Heinz Weiss. “Neurological worsening in Wilson disease — clinical classification and outcome.” Journal of Hepatology 79, no. 2 (2023): 321–328. https://doi.org/10.1016/j.jhep.2023.04.007. ↩↩
-
Litwin, Tomasz, Anna Czlonkowska, and Lukasz Smolinski. “Early neurological worsening in Wilson disease: The need for an evidence-based definition.” Journal of Hepatology 79, no. 6 (2023): e241–e242. https://doi.org/10.1016/j.jhep.2023.06.009. ↩
-
Alkhouri, Naim, Moises Gonzalez-Peralta, and Valentina Medici. “Wilson disease: a summary of the updated AASLD Practice Guidance.” Hepatology Communications 7, no. 6 (2023). https://doi.org/10.1097/HC9.0000000000000150. ↩
-
Kundu, G. “Outcome of low dose D-penicillamine therapy of neurologic Wilson disease — a longitudinal observational study.” Journal of the Neurological Sciences 429 (2021): 117874. https://doi.org/10.1016/j.jns.2021.117874. ↩
Esto es educación para pacientes, no asesoramiento médico. Consulta siempre a tu propio equipo clínico sobre las decisiones de tu tratamiento.